Cetrelimab (JNJ 63723283; JNJ 3283) is a humanized IgG4?? monoclonal antibody that selectively targets the programmed death-1 (PD-1) receptor. This antibody exhibits a high affinity for PD-1 with a dissociation constant (Kd) of 1.72 nM, as determined in HEK293 cells. Cetrelimab effectively inhibits the interaction between PD-1 and its ligands, PD-L1 and PD-L2, with half-maximal inhibitory concentrations (IC50) of 111.7 ng/mL and 138.6 ng/mL, respectively. By blocking this pathway, Cetrelimab activates peripheral T cells, leading to enhanced production of key cytokines such as interferon-gamma (IFN-??), interleukin-2 (IL-2), and tumor necrosis factor-alpha (TNF-??). This immunomodulatory effect contributes to its ability to suppress tumor growth in vivo, making it a valuable tool for cancer immunotherapy research.
Cetrelimab (JNJ 63723283; JNJ 3283) is a humanized IgG4?? monoclonal antibody that selectively targets the programmed death-1 (PD-1) receptor. This antibody exhibits a high affinity for PD-1 with a dissociation constant (Kd) of 1.72 nM, as determined in HEK293 cells. Cetrelimab effectively inhibits the interaction between PD-1 and its ligands, PD-L1 and PD-L2, with half-maximal inhibitory concentrations (IC50) of 111.7 ng/mL and 138.6 ng/mL, respectively. By blocking this pathway, Cetrelimab activates peripheral T cells, leading to enhanced production of key cytokines such as interferon-gamma (IFN-??), interleukin-2 (IL-2), and tumor necrosis factor-alpha (TNF-??). This immunomodulatory effect contributes to its ability to suppress tumor growth in vivo, making it a valuable tool for cancer immunotherapy research.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
